Clinical Trial Update: Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating camrelizumab with or without apatinib mesylate as first-line treatment in PD-L1 positive relapsed or advanced non-small cell lung can…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Apatinib Mesylate (apatinib)
• Camrelizumab (camrelizumab)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: PD-L1 Positive Non-small Cell Lung Cancer | Phase 3 | Status: UNKNOWN